Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by princeofcuton Apr 15, 2015 4:51pm

114 Views

Post# 23633855

RE:RE:Lesson from ESPR

ROTFLMAO...pickupstix and leakyboat a couple of regular old class clowns...as i understand you own and tout BTI relentlessly and BTI as i understand is 7 years pre-clinal status and has touters constantly touting the potential for some "deal" way too funny...let me help you out all pre-revenue biotechs are nothing but spec plays and PIII is less spec than PII which is less spec than PI which is less spec than pre-clinical period..but keep posting i love the laugh fest you are..here is my grand free advice for all baby bio investors, hedge your positions before any likely trial results..carry on

Bullboard Posts

Thesis Gold makes high-grade discovery at Ring Zone